McKesson Chosen as Specialty Pharmacy for OJEMDATM for Pediatric Low-Grade Glioma Treatment

Day One Biopharmaceuticals has selected Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, as a limited network specialty pharmacy for OJEMDATM (tovorafenib), approved by the U.S. Food and Drug Administration (FDA) on April 23, 2024. OJEMDA is an oral, brain-penetrant, highly selective type II RAF kinase inhibitor specifically designed for the treatment of pediatric low-grade glioma (pLGG). Recognized for its commitment to customer service and innovative approach, Biologics by McKesson is honored to provide this new therapy option for patients impacted by pLGG, demonstrating its dedication to patient care and access to innovative treatments.